Small sample sizes in each treatment group (EFG n=5, PE n=4, IVIg n=8), limiting statistical power and generalizability of findings across treatment modalities.

The gap

Consensus across the literature

Supporting evidence — 3 representative gaps

• Rapid neurological recovery in Guillain-Barré syndrome treated with efgartigimod (2026) · doi

  Small sample sizes in each treatment group (EFG n=5, PE n=4, IVIg n=8), limiting statistical power and generalizability of findings across treatment modalities.

  Keywords: treatment small sample sizes group ivig limiting statistical power generalizability across modalities
• Suppression of pathological oscillations with transcranial focused ultrasound in Parkinson’s disease (2026) · doi

  Owing to the small sample size, only a limited number of comparisons were made a priori, restricting the statistical power and generalizability of the findings.

  Keywords: owing small sample size limited number comparisons made priori restricting statistical power generalizability
• Non-invasive prenatal diagnosis of beta-thalassemia disease using digital PCR (2026) · doi

  Small sample size could limit the generalizability of the findings, particularly when considering diverse populations or rare mutations. Larger cohort studies involving participants with wider genetic backgrounds and mutation types would provide more robust and externally valid data.

  Keywords: small sample size limit generalizability particularly considering diverse populations rare mutations larger cohort involving participants